Breaking News

Irisys to Manufacture BioCorRx’s Opioid Use Disorder Treatment

BICX102 can help prevent relapse following opioid detoxification.

By: Contract Pharma

Contract Pharma Staff

Irisys LLC is providing contract development and GMP manufacturing services to BioCorRx Pharmaceuticals Inc. for a sterile naltrexone sub-cutaneous implant, also known as BICX102, which is meant to help in the treatment of opioid use disorder (OUD) and the prevention of relapse following opioid detoxification. BICX102 also shows promise for the treatment of alcohol use disorder (AUD).   Opioid addiction is considered a national crisis in the United States. Currently, 21%-29% of prescribed opioid...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters